Edition:
United States

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

13.22USD
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
$13.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,800
52-wk High
$18.90
52-wk Low
$11.51

Summary

Name Age Since Current Position

Alf Nicklasson

63 2015 Independent Chairman of the Board

Britt Meelby Jensen

45 2015 President, Chief Executive Officer, Member of the Executive Management

Rosemary Crane

58 2015 Independent Vice Chairman of the Board

Mats Blom

53 2017 Chief Financial Officer, Executive Vice President, Member of the Executive Management

Ivan Moeller

46 2018 Senior Vice President, Technical Development & Operations

Andrew Parker

53 2017 Executive Vice President, Chief Scientific Officer

Adam Steensberg

44 2017 Executive Vice President, Chief Medical and Development Officer (CMDO)

Marino Garcia

51 2018 Senior Vice President, Corporate and Business Development

Hanne Heidenheim Bak

65 2016 Director, Employee Representative

Jens Stenvang

64 2014 Director, Employee Representative

Kirsten Drejer

2018 Independent Director

Catherine Moukheibir

59 2015 Independent Director

Alain Munoz

69 2007 Independent Director

Michael Owen

67 2012 Independent Director

Biographies

Name Description

Alf Nicklasson

Dr. Alf Gunnar Martin (Martin) Nicklasson, Ph.D. has been Independent Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Martin has held broad-based executive experience from positions in European pharmaceutical and biotech companies. He held executive vice president positions at AstraZeneca PLC and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this, he held a number of leadership positions at AB Astra and Kabi Pharmacia AB. Martin Nicklasson is chairman of the board of Orexo AB and Kymab Ltd., as well as Board Member of Basilea Pharmaceutica Ltd. He is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Britt Meelby Jensen

Ms. Britt Meelby Jensen has been President, Chief Executive Officer and Member of the Executive Management of Zealand Pharma A/S since January 15, 2015. Prior to joining Zealand, she headed the Agilent-owned Danish diagnostics company, Dako, as the company’s CEO. Britt has experience from a range of managerial positions within the life science industry, including 11 years of international experience with Novo Nordisk. At Novo Nordisk, she held various global leadership positions, including head of Diabetes Marketing Nordic, Global Diabetes Lifecycle Management, prelaunch commercial projects and more recently Corporate Vice President for Global Marketing, Market Access and Commercial Excellence. Previously, Britt has worked for McKinsey and Company and within the EU Institutions in Brussels. She holds a M.Sc. from Copenhagen Business School, Denmark and an MBA from Solvay Business School in Brussels, Belgium.

Rosemary Crane

Ms. Rosemary A. Crane has been Independent Vice Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Ms. Rosemary Crane has been CEO of Mela Sciences (2013-2014) and Epocrates (2008-2011), besides having held a number of senior positions in Johnson & Johnson and BMS. She is Member of the Board of Teva Pharmaceutical Industries Ltd. and Edge Therapeutics. Rose has a BA in Communication from the State University of New York, MBA from Kent State University.

Mats Blom

Mr. Mats Peter Blom has been Executive Vice President, Chief Financial Officer and Member of the Executive Management at Zealand Pharma A/S since 2017. He has previously been Senior Vice President, Chief Financial Officer and Member of the Executive Management since January 3, 2011. Before that, he has been Vice President and CFO of the Company since March 1, 2010. He served as CFO at Swedish Orphan International. He has managerial experience and has held CFO positions at Active Biotech and Anoto both publicly listed on Nasdaq Stockholm. Previously, Mats worked for several years as a management consultant at Gemini Consulting and at Ernst & Young’s Transaction Services division. He holds a BA in Business Administration and Economics from the University of Lund followed by an MBA from IESE University of Navarra, Barcelona. Mats is Chairman of the Board for Medical Need AB and Board Member of Auris Medical AG.

Ivan Moeller

Mr. Ivan Moeller has been appointed Senior Vice President, Technical Development & Operations at ZEALAND PHARMA A/S, effective as of March 1, 2018. He brings experience from numerous senior management positions in the international pharmaceutical industry, including roles at Novartis in both generics and pharmaceutical manufacturing, as well as strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the U.S. and Switzerland. Prior to joining Novartis, Ivan Moeller was project leader at The Boston Consulting Group in New York, NY where he led client engagements in the pharmaceutical R&D and manufacturing areas. He started his career at PolyPeptide Laboratories where he was Head of Production site. He holds a Master of Science in Chemical Engineering from the Technical University of Denmark (DTU) and a Master of Business Administration from Harvard Business School.

Andrew Parker

Mr. Andrew Parker has been Executive Vice President and Chief Scientific Officer of Zealand Pharma A/S since 2017. He has previously been Senior Vice President and Chief Scientific Officer since July 1, 2016. He comes from a position as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2 & Cie SCPC in Switzerland. In parallel, he has held the position as CEO for Arisgen SA (an Eclosion2 portfolio company developing an oral peptide drug delivery technology). Andrew has more than twenty years of experience from senior leadership and managerial positions in international pharmaceutical, biotech and start-up companies, including several years with Shire Pharmaceuticals, Opsona Therapeutics, and AstraZeneca to mention a few. He holds a Ph.D. from the National Institute for Medical Research at Mill Hill, London, conducted post-doctoral research at Johns Hopkins Medical School, Baltimore, USA, and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 scientific articles in international journals.

Adam Steensberg

Mr. Adam Steensberg has been Executive Vice President, Chief Medical and Development Officer (CMDO) at Zealand Pharma A/S since 2017. He has previously been Senior Vice President and Chief Medical and Development Officer at Zealand Pharma A/S since March 19, 2015. Mr. Adam Steensberg joined Zealand in 2010 as Head of Clinical Development. Since 2011 he has been leading all development activities. Prior to joining Zealand, Adam has led several clinical research teams as medical director at Novo Nordisk A/S, and he has experience as clinician from the University hospital of Copenhagen. He has served as medical and scientific advisor within endocrinology, cardiology, gastroenterology, and rheumatology. He has experience with leading regulatory strategies and has been instrumental in implementing a patient-centric discovery and development process at Zealand. Adam has published more than 45 peer-reviewed scientific papers in international journals. Adam holds a Doctor of medicine followed by a Doctor of Medical Sciences (DMSc/ dr.med) from the University of Copenhagen, Denmark and an MBA from IMD, Switzerland.

Marino Garcia

Mr. Marino Garcia is Senior Vice President, Corporate and Business Development of the Company. Marino holds a Bachelor’s Degree in Business Administration from Concordia University in Montreal, Quebec, and an MBA from the Richard Ivey School of Business at Western University in London, Ontario. Prior to joining Zealand, Marino was instrumental in leading business development and corporate strategy at Synergy Pharmaceuticals Inc. Marino has more than 20 years of global experience in commercial, operational, corporate strategy, and business development. He has held various U.S. and international leadership roles of increasing responsibility at pharmaceutical companies, including Aptalis Pharma, Aspreva Pharmaceuticals, Eli Lilly & Co, Schering Plough, and Pfizer.

Hanne Heidenheim Bak

Ms. Hanne Heidenheim Bak has been appointed Director, Employee Representative at Zealand Pharma A/S, effective as of April 19, 2016. She previously held that position at the Company from April 17, 2012 to April 29, 2014. She is Senior Project Director, GI, External Relations and Collaborations and she holds M.Sc. (Pharm) from the Danish University of Pharmaceutical Sciences. Prior to joining Zealand in 2006, Hanne H. Bak worked 8 years as Project Manager of late-phase development programs at H. Lundbeck A/S, followed by 9 years as Executive Director at the Lundbeck Institute.

Jens Stenvang

Mr. Jens Peter Stenvang has been appointed Employee Representative on the Board of Directors of Zealand Pharma A/S, effective as of April 29, 2014. He holds a degree as laboratory technician in Biology. He has worked with cancer and diabetes research at universities including UC-Berkeley, California. Before joining Zealand in October 2010, Jens Peter worked for DAKO and Beckman Coulter as global Flow Cytometry support. Jens Peter has been member of the board of Dansk Selskab for Flowcytometri since 1990, excluding a short break from 2010-2012.

Kirsten Drejer

Dr. Kirsten A. Drejer has been Independent Director at ZEALAND PHARMA A/S since April 19, 2018. She holds PhD in Pharmacology and a MSc in Pharmacy from the University of Copenhagen. Kirsten Drejer is co-founder and previous CEO of Symphogen A/S (2000-2016) which is a privately biotech company dedicated to the development of mAb mixtures to provide effective treatments to serious diseases including with oncology. Dr. Drejer holds more than 30 years of international experience in the pharmaceutical and biotech industry. Before co-founding Symphogen A/S in 2000, Kirsten Drejer held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. In addition to her position as member of the board of directors of Symphogen A/S she holds board seats with Bioneer A/S (Chairman), Bioporto A/S, Lyhne & Co, Antag Therapeutics ApS and ResoTher Pharma ApS. Additionally, she is on the Advisory Board for The Faculty of Pharmaceutical Sciences, University of Copenhagen and the Entrepreneurship Advisory Board at Copenhagen Business School.

Catherine Moukheibir

Mrs. Catherine Moukheibir has been Independent Director of Zealand Pharma A/S since April 21, 2015. She has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy at various stages of a biotech’s development, and she is currently Member of the Board of Ablynx NV, Orphazyme, GenKyoTex and Cerenis Therapeutics Holding SA, as well as Chairman of the Board of MedDay Pharmaceuticals S.A. and Member of the Advisory Board of the Yale School of Management and Imperial College Business School. Ms. Catherine Moukheibir holds an MBA from Yale University.

Alain Munoz

Dr. Alain Munoz, Ph.D. has been Independent Member of the Board of Directors at Zealand Pharma A/S since 2007. He served as Director of the Company from 2005 until 2006 when he resigned. Alain Munoz has over 20 years of experience in the pharmaceutical industry at senior management level. Within the Sanofi Group he served as SVP for International development and in Fournier Laboratories as SVP for the Pharmaceutical division. He is Chairman of the Board of Hybrigenics SA and member of the Board of Valneva SE. Moreover, he is adviser to Kurma Biofund and Independent Board Member at Oxthera. Alain Munoz holds an MD in Cardiology and Anaesthesiology from the Hospital Pitie-Salpetriere, Paris. He has numerous publications and has been a member of the scientific committee of the French Drug Agency (ANSM).

Michael Owen

Dr. Michael John Owen has been Independent Director at Zealand Pharma A/S since 2012. Michael J. Owen is co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organization and Fellowship of the Academy of Medical Sciences. He is Member of the board of Blink Biomedical SAS, Avacta Group plc, GammaDelta Therapeutics, Glythera Ltd and ReNeuron Group plc. Moreover, he is advisor to CRT Pioneer Fund LP and Chairman of the Board of Ossianix Inc. He holds Doctorate in Philosophy degree in Biochemistry (Amino and Acid Transport in Trypanosomes) from Cambridge University and Bachelor of Arts degree in Biochemistry from Keble College, Oxford University.

Basic Compensation